Latest Articles and Analysis

Lupus Colorado partnership with CANN demonstrates how disease-specific and multi-condition advocates amplify healthcare policy impact.

Personal narrative on becoming an HIV advocate and the gratitude found in fighting for healthcare access from lived experience.

Pharmaceutical industry engagement of patient advocates requires transparency about funding, conflicts of interest, and advocacy independence.

Celebrity HIV misinformation directly impacts testing rates and perpetuates harmful stigma.

Strategies to address HIV-related stigma and its role in the epidemic.

HIV organizations face generational leadership transitions; racial equity in leadership roles needed.

Access Health Louisiana uses animated series and radio to educate communities on HIV, HCV, and public health.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

Explores the personal toll of patient advocacy, examining burnout and the need to support advocates.

Overview of the 340B Drug Discount Program for patient advocates covering program history and key policy issues.

Broken advocacy pipeline lacks investment in leadership development, compensation, and mentorship.